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Abstract
Several inborn errors of metabolism show cutis laxa as a highly recognizable
feature. One group of these metabolic cutis laxa conditions is autosomal reces-
sive cutis laxa type 2 caused by defects in v-ATPase components or the mito-
chondrial proline cycle. Besides cutis laxa, muscular hypotonia and cardiac
abnormalities are hallmarks of autosomal recessive cutis laxa type 2D
(ARCL2D) due to pathogenic variants in ATP6V1A encoding subunit A of the
v-ATPase. Here, we report on three affected individuals from two families with
ARCL2D in whom we performed whole exome and Sanger sequencing. We
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performed functional studies in fibroblasts from one individual, summarized
all known probands' clinical, molecular, and biochemical features and com-
pared them, also to other metabolic forms of cutis laxa. We identified novel
missense and the first nonsense variant strongly affecting ATP6V1A expres-
sion. All six ARCL2D affected individuals show equally severe cutis laxa and
dysmorphism at birth. While for one no information was available, two died in
infancy and three are now adolescents with mild or absent intellectual disabil-
ity. Muscular weakness, ptosis, contractures, and elevated muscle enzymes
indicated a persistent myopathy. In cellular studies, a fragmented Golgi com-
partment, a delayed Brefeldin A-induced retrograde transport and glycosyla-
tion abnormalities were present in fibroblasts from two individuals. This is the
second and confirmatory report on pathogenic variants in ATP6V1A as the
cause of this extremely rare condition and the first to describe a nonsense
allele. Our data highlight the tremendous clinical variability of ATP6V1A
related phenotypes even within the same family.
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1 | INTRODUCTION
Cutis laxa (CL) is a phenotypic feature present in differ-
ent rare genetic multisystem diseases. Affected individ-
uals show lax, wrinkled and sometimes thin skin due to a
reduction of dermal elastic fibers leading to a progeroid
appearance. In addition, some CL conditions show meta-
bolic changes such as alterations affecting cellular copper
levels, protein glycosylation, and mitochondrial amino
acid metabolism.1-7 Two examples are the conditions due
to pathogenic variants affecting the mitochondrial com-
ponents PYCR1 (ARCL2B; OMIM: 612940 and ARCL3B
614 438) and P5CS (ARCL3A; OMIM 219150 and
ADCL3; OMIM: 616603). The affected individuals show
an overall progeroid appearance, a typical triangular
facial gestalt with cataracts, contractures, and in some
lowered levels of plasma proline, arginine, or orni-
thine.3,4,6 Another group are the conditions showing
altered serum protein glycosylation due to pathogenic
variants affecting components of the highly conserved
vacuolar-type H+-ATPases. These are large protein com-
plexes, composed of two multicomponent sectors, V0 and
V1 fulfilling diverse physiological functions. The V0 sector
is membrane embedded and is responsible for proton
translocation across the membrane. V0 is composed of a
proteolipid ring of 10 c and individual a, d, e, ap1 and
ap2 subunits. The peripheral V1 sector is composed of
three A, B2, E1, G2, and single C1, D, and F subunits. Its
function is ATP hydrolysis providing energy for the
rotation of the central rotor subcomplex thereby facilitat-
ing proton translocation through the membrane via the
V0 sector.
8 v-ATPases are mainly involved in the regula-
tion of cellular pH homeostasis and in acidification of
intracellular compartments such as endosomes, lyso-
somes, the Golgi apparatus, and secretory vesicles. Addi-
tionally, they play several roles in endocytosis and
intracellular trafficking processes and regulate intracellu-
lar signaling pathways.9
Pathogenic variants affecting different v-ATPase com-
ponents lead to various forms of rare Mendelian disor-
ders ranging from severe osteopetrosis over renal acidosis
conditions to the diseases associated with cutis laxa.5,10,11
It has been shown that pathogenic variants in
ATP6V0A2, encoding the a2 subunit of the v-ATPase V0
sector, cause autosomal recessive cutis laxa type 2A
(ARCL2A; OMIM: 219200) and its allelic disorder Wrin-
kly skin syndrome (WSS; OMIM: 278250).5 The affected
individuals mainly show generalized cutis laxa, delayed
closure of the anterior fontanel, and downslanting
Synopsis
This study expands our knowledge about
ATP6V1A related cutis laxa and the postnatal car-
diac decompensation leading to death of some
individuals stresses the fact that these patients
need neonatal intensive care.
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palpebral fissures. Neurologically, they show a variable
degree of developmental delay, a cobblestone-like brain
malformation, seizures, and in some cases neu-
rodegeneration. Biochemically, affected individuals pre-
sent a congenital defect of glycosylation (CDG).2,5,12,13
Additionally, pathogenic variants affecting the accessory
v-ATPase subunits ATP6AP1 (CDG2S; OMIM: 300972)
and APT6AP2 (CDG2R; OMIM: 301045) have been
shown as a cause of rare multisystem conditions with
immunodeficiency and CL, associated with liver dysfunc-
tion and altered protein glycosylation.14,15
In 2017, pathogenic variants in two other subunits
of the v-ATPase have been described to be causative for
severely progeroid conditions with cutis laxa. Biallelic
pathogenic variants in ATP6V1E1, encoding the E1
subunit of the V1 sector, have been shown to cause
autosomal recessive cutis laxa type 2C (ARCL2C;
OMIM: 617402). Besides congenital cutis laxa affected
individuals show cardiac abnormalities, a triangular,
mask-like facial appearance and sometimes congenital
cataracts, leading to a strong progeroid appearance.1,16
Pathogenic variants affecting ATP6V1A, encoding the A
subunit of the V1 sector have been shown as the cause
of autosomal recessive cutis laxa type 2D (ARCL2D;
OMIM: 617403). These affected individuals also show
strong cutis laxa with redundant skin at birth. The
facial appearance is similar to ARCL2C affected
individuals.1,17 Some affected individuals present with
cardiac abnormalities and seizures.1 Additionally, in
affected individuals with pathogenic variants in
ATP6V1E1 and ATP6V1A alterations of serum transfer-
rin glycosylation as well as a reduced number of
ICAM-1 positive cells have been described previously
classifying these conditions as a CDG.1
In the present study, we report on the clinical and
molecular features of three affected individuals with a
severely progeroid form of congenital cutis laxa with gen-
eralized muscular hypotonia.
2 | AFFECTED INDIVIDUALS AND
METHODS
2.1 | Affected individuals
In this study, we report on two affected individuals from
a Hungarian and an affected boy from a Turkish family
with a severe cutis laxa phenotype at birth. From pro-
band A-II-2, a skin biopsy was taken, and dermal fibro-
blasts were cultivated according to standard procedures.
DNA from all affected individuals was isolated from
peripheral blood samples.
2.2 | Whole exome sequencing and co-
segregation
2.2.1 | Affected individual A-II-2
Enrichment for whole exome sequencing (WES) was
carried out using the SureSelect XT, Clinical research
exome V6 (Ilumina). Next generation sequencing was
performed on a HiSeq 4000 (Ilumina). The reads were
aligned using BWA-MEMv0.7.15 to the reference
GRCh37 (hs37d5.fa), separate read groups were assigned
for all reads from one lane, and duplicates were masked
using Samblaster v0.1.24.18 Standard QC was performed
using FastQC. The variants were called using GATK
Unified Genotyper v3.7 and were filtered using Varfish19
and MutationDistiller.20 Due to the clinical diagnosis,
we used for variant interpretation a virtual gene panel
for all genes associated with cutis laxa and removed var-
iants with a population frequency above 1% found in
gnomAD and the 1000 genomes project (TGP). Using
this approach, we detected two suspicious variants in
ATP6V1A. In silico predictions of pathogenicity were
performed by Mutation Taster,20,21 Polyphen-2,22 and
MetaDome.23 All variants were classified by the ACMG
guidelines.24 Sanger sequencing was performed of
ATP6V0A2 (NM_012463.4) and pathogenic variants
have been excluded in the affected individual A-II-2.
2.2.2 | Affected individual B-II-1
WES was performed by the Genomics Platform at the
Broad Institute of MIT and Harvard, Cambridge, USA.
Libraries were created with an Illumina exome capture
(38 Mb target) and sequenced with a mean target cover-
age of >80x. Genomic and phenotypic data were submit-
ted to the RD-Connect Genome-Phenome Analysis
Platform, GPAP, (https://platform.rd-connect.eu), where
they can be accessed under a controlled access agree-
ment. Exome sequencing data were processed and ana-
lyzed on the RD-Connect GPAP. Likely pathogenic
variants were identified applying standard filtering for
high to moderate variant effect predictor (ie, nonsense,
splice site, frame-shift, in-frame and non-synonymous
variants), and for minor allele frequency < 1% in
gnomAD (http://gnomad.broadinstitute.org), and in a
cohort of 1182 ethnically matched Turkish control indi-
viduals (TUBITAK MAM-GMBE dataset: http://gmbe.
mam.tubitak.gov.tr/en). Shortlisted variants were interro-
gated for their predicted in silico deleteriousness, previ-
ous known association with human disease and were
classified by the ACMG Guidelines.24
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For co-segregation analysis, the affected exons of
ATP6V1A (NM_001690.3) were sequenced in the
affected individuals and their parents when material
was available. Sequencing reaction was performed
using the BigDye Terminator cycle sequencing kit
(ThermoFisher Scientific), and run on a 3730 DNA
Analyzer (Applied Biosystems). Sequences were evalu-
ated and compared to reference sequences using
SeqMan (DNASTAR).
2.3 | Muscle histology
Histological studies on the quadriceps biopsy derived
from index patient B-II-1 were carried out as described
before.25 Immunofluorescence studies on the same biopsy
were performed following a recently published protocol26
utilizing a LAMP2 antibody (monoclonal mouse H4B4;
kindly provided by Prof. M. Vorgerd).
2.4 | Cell culture
Dermal fibroblasts from individual A-II-2 (obtained from
the Muscle Tissue Culture Collection MTCC, Munich,
Germany) and from control individuals were cultivated
in DMEM (Lonza) supplemented with 10% fetal calf
serum (Gibco), 1% UltraGlutamine (Lonza) and 1% peni-
cillin/streptomycin (Lonza).
2.5 | mRNA expression analysis
Cells were lysed in a confluent status with TRIzol
(Invitrogen) and total RNA was prepared by a standard
RNA extraction protocol. Total cDNA was reverse tran-
scribed by RevertAid H Minus First Strand cDNA Synthe-
sis Kit (Fermentas). Quantitative PCR was performed
using EVAgreen (Solis BioDyne) on a QuantStudio
3 Real-Time-PCR System (ThermoFisher Scientific). Sig-
nificance levels were calculated using Student's t-test.
Additionally, PCR amplicons of the regions affected by
the pathogenic variants from cDNA were generated and
subsequently sequences as described above. All primer
sequences are available in Table S1.
2.6 | Immunoblot
Cells were lysed with RIPA buffer (150 mM NaCl, 50 mM
Tris, 5 mM EDTA, 1% Triton X-100, 0.25% deoxycholate,
and 0.1% SDS) supplemented with protease inhibitor
(Complete, Roche). The 20 μg of protein per lane were
separated by SDS-PAGE and subsequently transferred to
nitrocellulose membrane. After semidry blotting mem-
branes were blocked 1 hour with blocking buffer (LI-
COR Biosciences) and probed with an antibody against
ATP6V1A (1:1000, Abcam) and GAPDH (1:40 000,
Ambion) overnight. Membranes were washed and incu-
bated with HRP- or IRDye-conjugated secondary anti-
bodies. Signals were detected with Odyssey FC Imaging
System and densitometric quantification was performed
using Image Studio (LI-COR Biosciences). Significance
levels were calculated using Student's t-test.
2.7 | Brefeldin A-induced Golgi collapse
Fibroblasts from the affected individual A-II-2 and appro-
priated controls were seeded on coverslips. The day after
they were incubated with 5 μg/mL Brefeldin A (BFA) for
9 minutes and immediately fixed in 4% paraformaldehyde
for 10 minutes at room temperature. Cells were washed
three times in phosphate buffered saline (PBS) and after-
ward permeabilized and blocked with 0.1% saponin in 3%
BSA for 20 minutes at room temperature. Immunofluo-
rescence staining was performed for the Golgi markers
GM130 (mouse anti-GM130; BD Transduction Laborato-
ries) and giantin (rabbit anti-giantin; Covance) overnight
in 3% BSA in 1x PBS. Cells were washed three times in
PBS and secondary antibodies anti-mouse IgG Alexa
Fluor 555 (Invitrogen, Molecular Probes) and an anti-
rabbit IgG Alexa Fluor 488 (Invitrogen, Molecular Pro-
bes) were applied. DNA was stained by DAPI and cells
were mounted in Fluoromount G (SouthernBiotech). Pic-
tures were taken with a fluorescence microscope (BX60,
Olympus). At least 100 cells per sample were counted
and the experiment has been performed two times. Sig-
nificance levels were calculated using Student's t-test.
2.8 | Metabolic labeling of ManNAz
Fibroblasts from the affected individual A-II-2 and appro-
priated controls were seeded in optical 96-well plate. Addi-
tionally, control cells were preincubated with 2 μM
tunicamycin (TN, Sigma Aldrich). Next day cells were
incubated 6 hours with 50 μM tetraacetylated N-
azidoacetyl-mannosamine (ManNAz, Jena Bioscience).
Cells were washed three times with PBS, fixed 15 minutes
with 4% PFA and permeabilised for 15 minutes with 0.5%
Triton-X-100. After washing, cells were labeled with click
reaction solution (10 μM Fluor 488-Alkyne fluorescent
probe/150 μM CuSO4x5H2O/300 μM BTTAA/2.5 mM
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ascorbic acid/100 mM K2HPO4, in water) for 1 hour and
nuclei were stained by DAPI. The fluorescence intensities
of the Golgi apparatus from individual cells were
measured using Operetta High Content Imaging System
(PerkinElmer). The experiment was performed two times.
Significance levels were calculated using Student's t-test.
FIGURE 1 Legend on next page.
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3 | RESULTS
3.1 | Clinical presentation
The affected individuals A-II-1 and A-II-2 are the chil-
dren of healthy, unrelated parents of Hungarian origin.
Individual A-II-1 was born at 39 weeks of gestation with
a weight of 3590 g. During pregnancy, decreased fetal
movements were observed. At birth, he showed general-
ized cutis laxa with redundant skin and muscular hypoto-
nia. Additionally, he showed a mask-like facial
expression and an overall progeroid appearance
(Figure 1A). Postnatally, he suffered from respiratory dis-
tress and was ventilated for 8 days. He had a strong pectus
excavatum and bilateral proximal and distal leg weakness
and bilateral contractures of his hips and knees. A muscle
biopsy revealed increased connective and fatty tissue,
increased variability of fiber size, rounded fibers, some
central nuclei and degenerating fibers with vacuoles (data
not shown). Additionally, his creatine kinase (CK) was
strongly elevated 13 000 to 15 000 U/L (ref. <190 U/L).
His skin biopsy revealed a decrease of elastic fibers, colla-
gen fibers with irregular shape and vacuolation of basal
keratinocytes (data not shown). Chromosome analysis rev-
ealed a normal 46,XY karyotype. Additionally, molecular
genetic diagnostic screening for pathogenic variants in
SMN1, GSDII, ATP6V0A2, PYCR1, and ALDH18A1 did
not reveal any alterations. Additionally, transferrin isoelec-
tric focusing did not show any protein glycosylation abnor-
malities. He died at 8 days of age due to cardiac and
respiratory failure.
Individual A-II-2 was born after an uneventful preg-
nancy at 39 weeks of gestation with a weight of 3160 g
(−0.75 SD), a length of 48 cm (−1.7 SD), and an OFC of
35.5 cm (+0.17 SD). At birth, he showed generalized cutis
laxa with redundant skin, muscular hypotonia, and ptosis.
A mask-like, triangular facial appearance with a short fore-
head, hypertelorism and an entropion were evident. Due to
respiratory distress, he was ventilated for 3 days after birth.
He had joint laxity, sat with support and spoke a few words
at 24 months and walked with support at 28 months of age.
Heart ultrasound was normal at 18 months of age. Cranial
MRI showed a thinning of the corpus callosum. A muscle
biopsy revealed degenerating fibers with vacuoles implying
a vacuolar myopathy in single fibers (data not shown) and
his creatine kinase (CK) was constantly elevated 392 to
1082 U/L (ref. < 190 U/L). At 1.5 years of age, the cutis laxa
did improve and he still showed a strong pectus excavatum
deformity (Figure 1B). Overall, the phenotype improved
with age and at 17 years of age, at the time of his last clini-
cal evaluation, he still had a facial dysmorphism, showed
thin skin and a weak muscle tone. However, his cognitive
parameters were in a normal range and he attended high
school. Chromosome analysis was performed and showed a
normal 46,XY karyotype.
Individual B-II-1 is the first child of consanguineous par-
ents of Turkish origin. After an uneventful pregnancy and
normal birth, generalized muscular hypotonia, retrognathia
and severe cutis laxa were recognized. The boy showed no
respiratory distress after birth. Motor milestones were
achieved in time (free sitting at 10 months of age, free walk-
ing at the age of 14 months). He showed normal speech and
cognitive development. At the age of 4 years a neuro-
pediatric consultation revealed general muscular hypotonia
and weakness, a pectus carinatum, cutis laxa, and facial dys-
morphism. Cranial MRI showed a cortical atrophy. Motor
and sensory neurography showed flattened amplitudes of
the muscle action potential and normal conduction veloci-
ties, thereby excluding a general neuropathy or significant
α-motoneuron decay. The serum creatine kinase level was
elevated up to 1980 U/L (ref. <190 U/L). Up to now, several
examinations excluded cardiac involvement. However, the
boy was examined twice a year with pulmonary function test
and developed a restrictive ventilatory problem with no
acute need for ventilation. At the age of 14 years, he devel-
oped a severe scoliosis, a spine surgery was performed. His
last visit at the age of 15 years revealed a normal endurance
and muscle strength without any progression or loss of
FIGURE 1 Clinical features of the affected individuals and disease gene identification. A, Both affected individuals A-II-1 and A-II-2
postnatally showed strong and generalized cutis laxa. Their facial gestalt was dysmorphic due to a triangular, mask-like, face with a short
and pointed chin. Additionally, individual A-II-2 showed a strong muscular hypotonia. B, Evolving phenotype in proband A-II-2 shows a
strong improvement of the cutis laxa phenotype from 1.5 to 17 years of age. With 1.5 years of age he still showed an entropion and a strong
pectus excavatum deformation. The cutis laxa phenotype improved within the first year of life. C, Histological findings: H&E staining
revealed myofibres displaying centralized nuclei as well as rimmed vacuoles (white arrows). Additional Gomori-trichrome staining shows
mitochondrial accumulation within one representative vacuoles (black arrow) as well as within the sarcoplasm (white arrow) in a
proportion of muscle cells. Acid phosphatase staining showed a positive reactivity of a proportion of vacuoles (black arrows) in addition to
sarcoplasmic deposits (white arrow). Prominent build-up of deposits of LAMP2 in a proportion of muscle fibers are respectively highlighted
by white arrows. D, Schematic view of the co-segregation analysis performed in both affected individuals from family A and their parents.
The substitution c.317 T > C; p.(Leu106Ser) was transmitted via maternal, whereas the alteration c.1513_1514del; p.(Asp505*) was inherited
through the paternal line. Both affected individuals were compound heterozygous. The alteration c.284 T > A; p.(Met95Lys) was found in a
homozygous state in the affected individual from family B
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motor functions. His overall phenotype, especially his cutis
laxa, improved with time and his cognitive parameters were
still in a normal range. Genetic analysis showed no muta-
tions in known genes for infantile myopathy.
3.2 | Muscle histology from individual
B-II-1
Histological examination of the quadriceps biopsy from
individual B-II-1 revealed a pronounced pathology char-
acterized by the presence of vacuoles of varying diame-
ter (Figure 1C, Figure S1), whereas some of these
vacuoles present empty, others are fuchsophil and/or
show a reactivity for acid phosphatase (Figure 1C).
Gomori-trichrome showed a sarcoplasmic increase of
mitochondria in a proportion of muscle fibers accompa-
nied by accumulation within vacuoles (Figure 1C). In
addition, NADH staining occasionally revealed focal
sarcoplasmic decrease of enzymatic activity supporting
the concept of irregular distribution of mitochondria in
a proportion of muscle cells (Figure S1). The periodic
acid-Schiff (PAS) reaction revealed increase of deposits
in a proportion of muscle fibers. Oil red staining showed
increased lipid deposits in a proportion of muscle fibers
(Figure S1). Additionally, immunofluorescence studies
revealed increased actin immunoreactivity in a minority
of myofibres. Myotilin, filamin C, and desmin showed
focal increase of reactivity suggestive for accumulation
of these structural proteins (Figue S1). Staining of
LAMP2, a known marker for the build-up of protein
aggregates revealed a profound sarcoplasmic increase in
the diseased muscle cells (Figure 1C). Of note, analysis
on caveolin-3 distribution showed—in addition to a reg-
ular sarcolemmal localization of the protein—a positive
immunoreactivity of the rim of vacuoles (Figure S1).
3.3 | Identification of the causative
genetic defect
To elucidate the molecular genetic cause of the observed
cutis laxa phenotype, we performed WES on the DNA
from the affected individuals A-II-2 and B-II-1. In both
samples we found suspicious variants in ATP6V1A. In
the affected individual A-II-2, we found two heterozygous
positions; however, the distance between them made it
impossible to judge on a potential compound heterozy-
gous situation from the WES data.
The variant c.317 T > C resides in exon 4 of ATP6V1A
and is predicted to cause a substitution from leucin at
position 106 of the ATP6V1A polypeptide to a serine p.
(Leu106Ser). This substitution is absent from all control
databases and predicted to be probably damaging by
MutationTaster, Polyphen-2, and Metadome (Table 1).
The variant c.1513_1514del is a deletion of two nucleo-
tides within exon 13, the penultimate exon of ATP6V1A
predicted to cause a frameshift. The consequence is the
immediate generation of a premature termination codon
p.(Asp505*). This alteration is also absent from all control
databases and predicted to be disease causing by
MutationTaster (Table 1).
To investigate whether this variant segregates with
the disease we performed co-segregation analyses by
Sanger sequencing using DNA samples from both
affected individuals and their clinically unaffected par-
ents. These analyses revealed the variant c.317 T > C; p.
(Leu106Ser) to be inherited through the maternal,
whereas the alteration c.1513_1514del; p.(Asp505*) was
transmitted via the paternal line. In both affected individ-
uals, we found both variants and can thus infer a com-
pound heterozygous situation, in line with an autosomal
recessive mode of inheritance (Figure 1D).
In individual B-II-1, we identified the variant
c.284 T > A in a homozygous state. It also resides in exon
4 of ATP6V1A and is predicted to cause the substitution
from methionine at position 95 of the ATP6V1A polypep-
tide to a lysin p.(Met95Lys) (Figure 1D). This substitution
is absent from all control databases and predicted to be
probably damaging by MutationTaster and Polyphen-2.
Unfortunately, no material from the clinically unaffected
parents was available. All variants identified in the
affected individuals have been classified as pathogenic
(class V) according to the ACMG criteria.
We investigated the conservation of the missense substi-
tutions affecting Met95 and Leu106 and found them in a
highly conserved (down to Xenopus laevis) part of the
ATP6V1A polypeptide (Figure 2A). Two different patho-
genic missense alleles, leading to ARCL2D have been
described previously.1 Additionally, Fassio et al found de
novo pathogenic missense variants causative for epileptic
encephalopathy in the same gene.27 Mapping the different
pathogenic alleles on the ATP6V1A genomic structure rev-
ealed no accumulation within a certain exon. However, the
variant p.(Asp505*) is to our knowledge the first predicted
nonsense allele identified in ATP6V1A (Figure 2B).
3.4 | Functional studies in dermal skin
fibroblasts
To further study the consequence of the identified vari-
ants, we performed quantitative RT-PCR to investigate the
expression of ATP6V1A and found in comparison to
healthy controls the ATP6V1A mRNA reduced by approxi-
mately 65% in the cells from the affected individual A-II-2
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(Figure 2C). To study this in more detail, PCR amplicons
including the alterations were generated from cDNA of
proband A-II-2. Subsequent Sanger sequencing revealed
the allele carrying the missense alteration p.(Leu106Ser) to
be expressed, whereas the allele harboring the nonsense
alteration was not detectable (Figure 2C). Additionally, we
investigated ATP6V1A protein levels using immunoblot
analysis of the fibroblasts from proband A-II-2 in compari-
son to controls. Using an antibody against ATP6V1A,
functionally validated in the literature,1 we found a band
with the expected size in all individuals analyzed. How-
ever, the band intensity was strongly reduced in the lysates
from the probands fibroblasts. Densitometric analyses
from three independent experiments revealed a reduction
of approximately 50% of band intensity proving a strong
reduction of ATP6V1A in fibroblasts from the affected
individual A-II-2 (Figure 2C).
Previously, it has been shown that loss-of-function
pathogenic variants in ATP6V0A2, ATP6V1A and
ATP6V1E1 lead to changes in Golgi function.1,2 In order
to evaluate whether this was also true for our cases we
stained the giantin protein to visualize the Golgi appara-
tus in fibroblasts from proband A-II-2 and matched con-
trols. Golgi morphology was clearly altered with swollen
and fragmented cisternae. Quantification revealed a frag-
mented Golgi apparatus in 26% of cells from the affected
individual A-II-2 in comparison to less than 10% in con-
trols (Figure 3A). Another phenomenon observed in
fibroblasts from affected individuals carrying pathogenic
variants in genes encoding v-ATPase components
(ATP6V0A2, ATP6VE1, and ATP6V1A) is a delayed retro-
grade transport from the Golgi apparatus to the endoplas-
mic reticulum (ER) transport induced by Brefeldin A
(BFA) treatment.1,2,5 To study the impact of BFA on the
fibroblasts from proband A-II-2, Golgi integrity was mea-
sured after 9 minutes BFA treatment. In control fibro-
blasts from three healthy individuals, below 25% of the
cells had a noncollapsed Golgi apparatus after this treat-
ment whereas in fibroblasts from individual A-II-2 36.5%
showed a preserved Golgi structure (Figure 3B).
Given these alterations of the Golgi compartment we
wanted to know whether protein glycosylation is altered in
the fibroblasts from proband A-II-2. This was investigated
using metabolic labelling of cells from individual A-II-2 and
healthy controls with ManNAz to track sialylated glycol-
conjugate metabolism. ManNAz is taken up by the cell via
an endocytosis independent mechanism and is intracellu-
larly converted into SiaNAz (azido N-acetylneuraminic
acid). Subsequently, this structure is incorporated into pro-
teins and lipids within the Golgi apparatus.28,29 Using this
method N-azidoacetyl-tagged sugars can be visualized by
adding a fluorophore on each modified molecule. The


















































































































































































































































































































































































































































































































980 VOGT ET AL.
measured using a high content screening system to assess
the efficiency of SiaNAz incorporation. We found in healthy
individuals fluorescence intensities in a range from 860 to
920 fluorescence units with an even distribution of single
values. In fibroblasts from individual A-II-2, a significant
reduction to 820 fluorescence units was detectable with a
strong accumulation of values below the median of the con-
trols. As a control experiment, we incubated control cells
FIGURE 2 A, Conservation was investigated by an interspecies alignment. The residue Met95 and Leu106 are highly conserved down to
Xenopus laevis. B, Schematic overview of all so far described alterations identified within ATP6V1A. Above the exonic structure all variants
leading to ARCL2D are indicated including the two variants found in the present study (red). Below, all dominant de novo pathogenic
variants, causative for epileptic encephalopathy are indicated. C, Functional consequence of the pathogenic variants in ATP6V1A in
fibroblasts from individual A-II-2. Quantitative PCR was performed on cDNA extracted from fibroblasts from individual A-II-2 and controls.
ATP6V1A expression was significantly reduced in the cells from proband A-II-2 (**P < .01; ***P < .0005). Amplification of ATP6V1A
amplicons from individuals A-II-2 cDNA including the positions affected by the pathogenic variants. The two nucleotide deletion
c.1513_1514del was absent on cDNA level while the variant c.317 T > C encoding the variant p.(Leu106Ser) was detectable. Analysis of
ATP6V1A protein expression in individual A-II-2 fibroblasts revealed a significant reduction of protein expression by approximately
40% (*P < .05)
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FIGURE 3 Abnormal function of the Golgi apparatus: A, Morphology of the Golgi apparatus was evaluated using immunofluorescence
staining of Giantin. In control cells the Golgi apparatus showed regular cisternae whereas in proband A-II-2 fibroblasts the Golgi structure
was dilated and fragmented. In controls below 10% of cells showed a fragmented and dilated Golgi, whereas in the cells from individual A-
II-2 more than 25% of cells showed this fragmentation (**P < .01). Scale bar: 100 μm, B, Brefeldin A-induced Golgi collapse. All cells were
treated with BFA and Golgi collapse was measured in controls and cells from individual A-II-2 after 9 minutes. The Golgi collapse was
significantly reduced in the proband's cells in comparison to controls (**P < .01=; ns = not significant. Scale bar: 100 μm, C, Glycosylation
within the Golgi apparatus. Metabolic labelling of intra-Golgi sialylation via the analysis of SiaNAz incorporation. In cells from individual A-
II-2, we found a significant reduction of SiaNAz fluorescence indicating a glycosylation abnormality within the Golgi apparatus in
comparison to controls (***P < .0005). Scale bar: 100 μm
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with tunicamycin (TN), a glycosylation inhibitor, and found
a strong reduction of fluorescence intensity to 580 fluores-
cence units (Figure 3C).
4 | DISCUSSION
In the present study, we identified pathogenic variants in
ATP6V1A as the cause of a severe cutis laxa phenotype in
affected individuals from two unrelated families. The
observed phenotype with generalized cutis laxa, redun-
dant skin and a typical mask-like triangular face in all
affected individuals is in line with the already published
cases.1,17 Interestingly, the referring clinicians first
suspected ARCL2A due to facial similarity. It therefore
seems that there is a suggestive facial appearance caused
by mutations in ATP6V0A2, ATP6V1E1, and ATP6V1A.
The two boys from family A showed postnatal respiratory
distress and required ventilation for several days while
the affected individual B-II-1 developed restrictive venti-
latory problems later in life. The reason for this is cur-
rently unclear, but a delayed lung maturation or
diaphragmatic weakness are possible explanations for the
respiratory problems. Unfortunately, individual A-II-1
died at 8 days of age due to cardiac and respiratory fail-
ure. Individual PIV:1 described by van Damme et al also
showed cardiac failure.1 Thus, respiratory and cardiac
decompensation immediately after birth can lead to a
drastic discordance of the clinical outcome, even in sib-
lings. In contrast, the phenotype of individual A-II-2 and
B-II-1 improved considerably after they had survived the
postnatal period. A similar course was also described by
van Damme and colleagues.1,17 2/6 known affected indi-
viduals died within the first days or months of life.1 How-
ever, after overcoming this critical period, the further
development of the surviving individuals improved
over time.
In comparison to ATP6V0A2-related CL, where most
affected individuals show a variable degree of intellectual
disability, this feature is completely absent in the affected
individual A-II-2 and B-II-1 from this study and has been
not been previously described in others.1,17 In
ATP6V0A2-related CL one consistent feature is a cobble-
stone malformation and many affected individuals show
seizures. Also two-third of the previously reported individ-
uals with ATP6V1A pathogenic variants suffered from sei-
zures and some also showed polymicrogyria and a thin
corpus callosum (Table 1).1 In line with this, proband II-2
also showed a thinning of the corpus callosum and individ-
ual B-II-1 showed cortical atrophy. However, they never
developed seizures and are successful high school students.
The generalized muscular hypotonia described in
affected individuals with pathogenic variants in
ATP6V1E1 and ATP6V1A has also been observed in the
individuals A-II-1, A-II-2, and B-II-1 from this study
(Table 1). The muscle biopsy revealed degenerating
fibers with vacuoles characteristic for a metabolic myop-
athy. Additionally, histology revealed an increase and
irregular distribution of muscle mitochondria implying
a secondary mitochondrial dysfunction. Within the
spectrum of CL conditions the differential diagnoses
closest to ARCL2D are the forms due to pathogenic vari-
ants affecting the mitochondrial components PYCR1
and P5CS, all showing a progeroid appearance and
strong muscular hypotonia (Table 1).3,4,6 However, also
in ATP6V0A2 and ATP6V1E1 related cutis laxa, this is a
common feature (Table 1).30 So far it is not clear how
the Golgi apparatus and the mitochondria are inter-
connected. In all v-ATPase related CL conditions the
Golgi apparatus in patient derived cells shows an altered
morphology. This includes a dilatation and/or fragmen-
tation of this compartment.1,2 The same has been
observed in the cells from affected individual A-II-2
from this study. Additionally, the trafficking defect upon
BFA treatment is a specific feature for ATPase related
CL condition, which is absent in other CL conditions
(Table 1).2 This implies a functional defect of this com-
partment, potentially leading to secretion defects of
extracellular matrix components and other factors.
Interestingly, Ron Wevers and Eva Morava recently dis-
covered a pathogenic variant in PI4K2A, encoding pho-
sphatidylinositol 4-kinase type 2-alpha as the cause of a
CL condition with strong neurological features, move-
ment disorders and a marked myopathy.31 Golgi-derived
phosphoinositol-4-phosphate containing (PI(4)P) vesi-
cles were recently described to be involved in mitochon-
drial fission processes.32 In light of this work, one might
speculate that trans-Golgi network dysfunction and
intracellular trafficking problems due to loss of v-
ATPase components might secondarily affect mitochon-
drial function by a reduced availability of PI(4)P positive
vesicles.
The identified compound heterozygous pathogenic
variants in ATP6V1A have not been described previ-
ously and are absent from gnomAD and TGP. Addi-
tionally, they were predicted to be disease causing by
different in silico prediction tools and the affected
gene is in agreement with the phenotype leading to a
classification as a pathogenic variant according to the
ACMG criteria. The mutations p.(Met95Lys) and p.
(Leu106Ser) affect highly conserved residues within
the ATP6V1A polypeptide. The alteration p.(Met95Lys)
resides within a loop whereas the substitution p.
(Leu106Ser) affects the beginning of an alpha-helix.
Both substitutions change the properties on the respec-
tive position from a non-polar amino acid to a polar
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one, very likely interfering with structural properties
of the monomer. All variants in ATP6V1A causative
for ARCL2D known so far are missense variants lead-
ing to an instable V1 sector.
1 Therefore, it is likely that
the herein identified missense substitutions might also
cause an altered structure and thereby lead to a gener-
alized assembly problem of this sub-complex. The
identified nonsense pathogenic variant is the first
alteration of this kind detected in an individual with
ARCL2D. The allele carrying the nonsense alteration
completely underwent degradation as expected for this
type of variant. In line with these data, also ATP6V1A
protein expression was strongly reduced. The pheno-
type observed in ATP6V1A-related CL affected individ-
uals belongs to the most severe end of CL phenotypes
associated with pathogenic variants in ATPase compo-
nents. Therefore, and in line with the increased rate of
early postnatal lethality, one might speculate that
biallelic nonsense pathogenic variants in ATP6V1A are
not compatible with life in humans.
Another feature affected individuals with CL and
pathogenic variants in components of the v-ATPase
have is a congenital defect of glycosylation. In
ATP6V0A2 and ATP6V1E1 related CL, this is a constant
feature in the individuals tested; however, in ATP6V1A
this seems to be variable (Table 1).1 In two affected
individuals described by van Damme et al, this was
once detectable while it was absent in another test. In
proband A-II-1 from this study, transferrin isoelectric
focusing did not show any glycosylation abnormalities.
ATP6V1A pathogenic variants reduced the abundance
of ICAM-1 at the surface of fibroblasts, which is an
indication for a glycosylation defect. We decided to ana-
lyze N-glycosylation within the Golgi apparatus using a
pulse chase experiment with a precursor for sialic acid.
We found a significant reduction of sialylation within
this compartment, comparable to what was seen in
ATP6V0A2 deficient fibroblast.29
In conclusion, we herein report on three additional
affected individuals due to pathogenic variants in
ATP6V1A as the cause for a severe cutis laxa phenotype.
One of these variants is the first nonsense allele described
in this gene. This study expands our knowledge about this
extremely rare condition and the postnatal cardiac decom-
pensation leading to death of one sibling stresses the fact
that these patients may need neonatal intensive care.
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